PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

Summary

This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584. Subjects who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or non-compliance with the protocol requirement.

Timeline

Start

2005-11

Primary completion

2009-08

Completion

2010-06

Drugs

Indications